XML 31 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenues
 12 Months Ended
Dec. 31, 2024
Revenues [Abstract]  
Revenues Revenues
Product Revenue
The Company’s net product revenues consisted of the following for the years ended December 31:
20242023
Products:
Kristalose$15,315,259 $15,981,850 
Sancuso9,005,129 8,096,788 
Vibativ7,160,125 8,812,692 
Caldolor4,959,385 4,333,923 
Acetadote185,182 458,759 
Omeclamox(3,075)20,030 
Vaprisol(174,538)151,336 
RediTrex90,237 (341,886)
Total net product revenues$36,537,704 $37,513,492 
Other Revenues
The Company has agreements with international partners for commercialization of the Company’s products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
In the second quarter of 2023, the Company received $1 million relating to a litigation settlement based on two $500,000 milestone payments due to us for the license associated with our Vibativ product that is included in other revenue for the year ended December 31, 2023.
Other revenues includes funding from federal grant programs including those secured from the FDA and from those secured by CET through the Small Business Administration. Grant revenue from these federal grant programs totaled approximately $0.4 million for the years ended December 31, 2024 and 2023.
Other revenues also includes lease income generated by CET’s Life Sciences Center. It is a research facility that provides scientists with access to flexible lab space and other resources to develop biomedical products. This lease income, as noted in Footnote 15 - Leases, was approximately $0.6 million and $0.5 million and for the years ended December 31, 2024 and 2023, respectively.